Fundraising Fox
Kano Therapeutics
Cambridge, US · Founded 2021 · Delaware corporation · 6 known investors
Find your way into Kano Therapeutics
Sign up to find every way you can get introduced to Kano Therapeutics
- Your email: who you already know at Kano Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Kano Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Kano Therapeutics develops circular single-stranded DNA (cssDNA) as a genetic payload for gene-editing and other DNA-based therapies, offering an alternative to viral vectors and double-stranded DNA. It manufactures cssDNA via industrial fermentation and licenses and supplies the payload to therapeutic developers through integrated partnerships spanning discovery to GMP.
Founders & leadership
Board
Investors · 6
How we know: Fifty Years's portfolio page · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: Metaplanet's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: Vsquared Ventures's portfolio page · a partner's Signal profile · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$5M disclosed across 1 round · 2024
▶$5MraisedMay 2024 · 4 investors · BiotechnologyRule 506(b)
- Ann DeWittDirector
- Floris EngelhardtExecutive Officer, Director
- John VroomDirector
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- May 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
Companies working in the same space as Kano Therapeutics.
In the news
Frequently asked questions
- What does Kano Therapeutics do?
- Kano Therapeutics develops circular single-stranded DNA (cssDNA) as a genetic payload for gene-editing and other DNA-based therapies, offering an alternative to viral vectors and double-stranded DNA. It manufactures cssDNA via industrial fermentation and licenses and supplies the payload to therapeutic developers through integrated partnerships spanning discovery to GMP.
- Who are Kano Therapeutics's investors?
- Kano Therapeutics's investors include Fifty Years, Launchpad Venture Group, Metaplanet, The Engine Ventures, Vsquared Ventures, ZAKA VC.
- How much funding has Kano Therapeutics raised?
- Kano Therapeutics has disclosed $5M raised across 1 round.
- Where is Kano Therapeutics headquartered?
- Kano Therapeutics is headquartered in Cambridge, US.